Effects of the New Aldose Reductase Inhibitor Benzofuroxane Derivative BF-5m on High Glucose Induced Prolongation of Cardiac QT Interval and Increase of Coronary Perfusion Pressure

Figure 3

(a) SIRT1 in perfused hearts following treatment with D-glucose 11.1 mM (control); glucose 11.1 mM + DMSO 1% (vehicle); glucose 33.3 mM (high glu); high glu + BF-5m (0.01, 0.05, and 0.1 μM); high glu + BF-5m (0.1 μM) + EX527 (10 mg/kg/day i.p.). Total RNA was extracted from the hearts and reverse transcribed into cDNA using superscript reverse transcriptase system. The expression of SIRT1 was quantified by qPCR using commercially available rat primers. Results are expressed as arbitrary units based on calculation of method. versus control; and versus high glu. (b) Addition of BF-5m (0.01, 0.05, and 0.1 μM) to the high glucose Krebs solution dose-dependently increased the expression of SIRT1. Results are derived from western blotting (panel (c) representative) and expressed as densitometric units (mean ± s.e.m. of observations for each group). Significant differences versus control are reported as and ; significant differences versus high glu are reported as and ; significant differences versus high glu + BF-5m 0.1 μM are reported as .

(a)

(b)

(c)